Skip to main content

A multiple myeloma clinical trial - MY13

A clinical trial comparing fewer or more treatment injections in older adults with multiple myeloma
Disease Site
Hematologic Clinical Trials
Trial Code
MY.13 ǀ NCT06182774
Trial Status
Open to patient enrollment

What is the purpose of this study?

One of the treatments for multiple myeloma is with three medicines, all continued indefinitely until they stop working, or side effects happen. Two are tablets, and the third is an injection. In this study, we are testing if the injection can be stopped after around 18 months of treatment with no change to how your multiple myeloma is being controlled.

Why is this study important?

There is a lack of information about the best length of injectable treatment. This study will help us understand if limiting the length of injectable treatment to 18 months is as good as the usual continuous treatment approach. We will also learn if less treatment may reduce side effects like infections and improve quality of life.

Who can participate in this study?

This trial is for:

  • People aged 18 years or older with newly diagnosed multiple myeloma who have received at least 18 months of therapy with the usual drugs, and whose disease has responded well.

This trial is not for:

  • People with non-secretory multiple myeloma or AL amyloidosis.
  • People who are having a stem cell transplant.
  • People who have an active and uncontrolled bacterial, fungal, or viral infection within 7 days prior to starting the study.
  • People who are pregnant or breastfeeding.

There are a few other criteria required for you to be allowed to participate. Your doctor can explain these.

What are the risks?
  • If you choose to take part in this study, there is a risk that stopping the treatment injection after 18 months may not be as good as the standard continuous combination drug therapy. There are risks of side effects, but these risks are anticipated to be no greater than for the current standard treatment with the three medicines.
What can I expect?
  • If you choose to take part in this study, you will be randomly placed in one of two groups. One group will continue to receive the same treatment they are already on, with injections and tablets. One group will stop the injection at around 18 months, continuing only on the tablets they are already taking. In this study, you will also be asked to complete a few questionnaires at different times to understand your Quality of Life.

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an Informed Consent document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The MY.13 study is enrolling patients at cancer centres in Canada. For a full list of participating centres please visit www.ClinicalTrials.gov and search using NCT06182774.

Use this trial information for your conversation with your health care team

Participating centres
  • Niagara Health System - St. Catharines, ON, L2S 0A9 - Contact: Dr. Huma Qawi
  • Juravinski Cancer Centre at Hamilton Health Sciences - Hamilton, ON, L8V 5C2 - Contact: Dr. Hira Mian
  • Lakeridge Health Oshawa - Oshawa, ON, L1G 2B9 - Contact: Dr. Ariah Joshua Schattner
  • Algoma District Cancer Program Sault Area Hospital - Sault Ste. Marie, ON, P6B 0A8 - Contact: Dr. Danny Hill